These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
434 related articles for article (PubMed ID: 24513913)
1. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Susantitaphong P; Alqahtani F; Jaber BL Am J Nephrol; 2014; 39(2):130-41. PubMed ID: 24513913 [TBL] [Abstract][Full Text] [Related]
2. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran. Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904 [TBL] [Abstract][Full Text] [Related]
3. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875 [TBL] [Abstract][Full Text] [Related]
4. Effect of ultrapure dialysate on markers of inflammation, oxidative stress, nutrition and anemia parameters: a meta-analysis. Susantitaphong P; Riella C; Jaber BL Nephrol Dial Transplant; 2013 Feb; 28(2):438-46. PubMed ID: 23291370 [TBL] [Abstract][Full Text] [Related]
5. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Vaziri ND Am J Kidney Dis; 2013 Jun; 61(6):992-1000. PubMed ID: 23375852 [TBL] [Abstract][Full Text] [Related]
6. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia? Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073 [TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Schiller B; Bhat P; Sharma A Clin Ther; 2014 Jan; 36(1):70-83. PubMed ID: 24315802 [TBL] [Abstract][Full Text] [Related]
8. It's time to compare anemia management strategies in hemodialysis. Coyne DW Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363 [TBL] [Abstract][Full Text] [Related]
9. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients. Chen YC; Hung SC; Tarng DC Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299 [TBL] [Abstract][Full Text] [Related]
10. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale. Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549 [TBL] [Abstract][Full Text] [Related]
11. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Attallah N; Osman-Malik Y; Frinak S; Besarab A Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942 [TBL] [Abstract][Full Text] [Related]
12. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Li H; Wang SX Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498 [TBL] [Abstract][Full Text] [Related]
13. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress. Swarnalatha G; Ram R; Neela P; Naidu MU; Dakshina Murty KV Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):852-8. PubMed ID: 20814119 [TBL] [Abstract][Full Text] [Related]
14. Effect of aggressively driven intravenous iron therapy on infectious complications in end-stage renal disease patients on maintenance hemodialysis. Bansal A; Sandhu G; Gupta I; Kalahalli S; Nayak R; Zouain E; Chitale RA; Meisels I; Chan G Am J Ther; 2014; 21(4):250-3. PubMed ID: 22832501 [TBL] [Abstract][Full Text] [Related]
15. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients. Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014 [TBL] [Abstract][Full Text] [Related]
16. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence. Singh A Semin Dial; 2009; 22(1):64-9. PubMed ID: 19175537 [TBL] [Abstract][Full Text] [Related]
17. The safety of intravenous iron dextran (Dexferrum) during hemodialysis in patients with end stage renal disease. Hood SA; O'Brien M; Higgins R Nephrol Nurs J; 2000 Feb; 27(1):41-2. PubMed ID: 10852689 [TBL] [Abstract][Full Text] [Related]
18. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178 [TBL] [Abstract][Full Text] [Related]
19. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. Kaneko Y; Miyazaki S; Hirasawa Y; Gejyo F; Suzuki M Kidney Int; 2003 Mar; 63(3):1086-93. PubMed ID: 12631092 [TBL] [Abstract][Full Text] [Related]